The European Commission's Directorate General for Competition will contribute to a public workshop organised by the United States’ Federal Trade Commission (“FTC”) and Department of Justice (“DOJ”) in the framework of the Multilateral Working Group on pharmaceutical mergers (the “Working Group”) formed in March 2021. Working Group members, which also include the Canadian Competition Bureau and the UK's Competition and Markets Authority, along with several representatives from academia will participate in the two-day public workshop to discuss key topics in the assessment of pharmaceutical mergers.
The workshop will take place virtually on 14 and 15 June 2022. Its purpose is to foster exchanges of experience, best practices and views between various stakeholders in the field including academics and enforcers. The workshop follows the public consultation launched by the Working Group in May 2021 and marks the completion of a cycle of discussions within the Working Group since then.
The workshop will be open to the public and broadcasted on the FTC’s website. Prior registration is not required, and the links will be made public on the day of the event on the FTC’s website.
- Datum der Veröffentlichung
- 31 Mai 2022